-
Mashup Score: 23PIRTOBRUTINIB IN RELAPSED/REFRACTORY CLL/SLL: RESULTS FROM BTKI... by Dr. Toby Eyre - 6 month(s) ago
EHA Library; Eyre T. Jun 13 2024; 420720;
Source: library.ehaweb.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0
EHA Library; Pollyea D. May 18 2017; 180699;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
Molecular Genetic Testing Patterns in Newly Dx AML: CONNECT® Registry [May 18, 2017] @DanPollyea et al. Abstract: E923 #EHA22 https://t.co/NOvxkVe5nr #NCT01688011 #AMLsm #leusm #oncopath #camoldx #PrecisionMedicine https://t.co/NwOTZTzC03
-
-
Mashup Score: 17MINI-CONSOLIDATIONS VERSUS INTERMEDIATE-DOSE CYTARABINE (IDAC) FOR... by Christian Récher - 6 month(s) ago
EHA Library; Récher C. Jun 13 2024; 422253;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
MINI-CONSOLIDATIONS VERSUS INTERMEDIATE-DOSE CYTARABINE (IDAC) FOR THE POST-REMISSION THERAPY OF AML PATIENTS OVER 60 https://t.co/SxwUcMAKhZ #leusm #EHA24 https://t.co/Hdg8Kca8l8
-
-
Mashup Score: 11COMPLETED DOSE ESCALATION FROM THE FIRST-IN-HUMAN, PHASE 1/2 STUDY... by Sylvain Garciaz - 6 month(s) ago
EHA Library; Garciaz S. Jun 13 2024; 422250;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
COMPLETED DOSE ESCALATION FROM THE FIRST-IN-HUMAN, PHASE 1/2 STUDY OF CD123 NK CELL ENGAGER, SAR443579, IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR HIGH RISK-MYELODYSPLASIA https://t.co/kWCQfxQJE9 #AML #leusm https://t.co/q0QC7cTuBN
-
-
Mashup Score: 50VENETOCLAX-HMA AS A BRIDGE TOWARDS HSCT OR DLI IN R/R AML: A... by Kathelijn Verdeyen - 6 month(s) ago
EHA Library; Verdeyen K. Jun 13 2024; 422241;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
VENETOCLAX-HMA AS A BRIDGE TOWARDS HSCT OR DLI IN R/R AML https://t.co/Uf8MspCzzQ #EHA24 #leusm https://t.co/rmgpqB2Hjd
-
-
Mashup Score: 7PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE WITH VENETOCLAX AND... by Alex Bataller - 6 month(s) ago
EHA Library; Bataller A. Jun 13 2024; 422243;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE WITH VENETOCLAX AND GILTERITINIB IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA https://t.co/h9l46o3bID #EHA24 #AML #leusm https://t.co/DyuMeDZ7UB
-
-
Mashup Score: 29
EHA Library; Ruhnke L. Jun 13 2024; 422239;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
VENETOCLAX-BASED SALVAGE TREATMENT FOR RELAPSED/REFRACTORY AML USING A COMBINATION WITH HIGH-DOSE CYTARABINE AND MITOXANTRONE (HAM-VEN): UPDATED RESULTS OF THE PHASE-I/II SAL RELAX TRIAL https://t.co/QEZ2yM0xl4 #EHA24 https://t.co/UwHHUUEpmg
-
-
Mashup Score: 37IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS (PTS) WITH CLINICAL... by Dr. Xavier Leleu - 6 month(s) ago
EHA Library; Leleu X. Jun 13 2024; 422312;
Source: library.ehaweb.orgCategories: General Medicine News, Partners & KOLsTweet-
👀 #EHA2024 KarMMa-2 cohort 2B: ide-cel CAR-T in functional high-risk ASCT-ineligible #MMsm. 2-yr PFS 63% 🤯 Cross-cohort comparisons tough, but in cohort 2A (fxnal high-risk but got ASCT) mPFS only 11.4 mo. I have theories but will wait for data! https://t.co/Zct2CxPBWy https://t.co/uGvYEldSWP
-
-
Mashup Score: 15
EHA Library; Dong S. Jun 13 2024; 420982;
Source: library.ehaweb.orgCategories: General Medicine News, Partners & KOLsTweet-
#EHA2024 Kudos to @sharlenedong @GKaurMD @flatironhealth for their analysis of carfilzomib dosing in R/R myeloma #MMsm. RWE from almost 500 pts: K56 1x wkly ≈ K56 2x wkly ≈ K70 1x wkly. For me, this ARROW points to K 56 1x weekly as the default! https://t.co/bUcL3v3zxX https://t.co/xtbJxXeeKZ
-
-
Mashup Score: 25LETERMOVIR FOR SECONDARY PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION... by Nihar Desai - 6 month(s) ago
EHA Library; Desai N. Jun 13 2024; 421891;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
We will present our experience of using Letermovir for SECONDARY PROPHYLAXIS of CMV after allogeneic stem cell transplantation at the @EHA_Hematology meeting in Madrid. Manuscript under review, should hopefully be published by then 🤞🏼 #MedTwitter https://t.co/RSHX1LJap9
-
How do BTKi-naive R/R CLL pts fare with #pirtobrutinib? ▶️▶️Check out results from the 35 BTKi-naive high genomic risk R/R CLL pt cohort with median of 2 prior lines from BRUIN at #EHA2024 https://t.co/1DS8z4CZZK https://t.co/BgRkHRP9PP